NCT04622774View on ClinicalTrials.gov

First-in-Human Study of IMGC936 in Participants With Advanced Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

October 29, 2020

Primary Completion Date

December 28, 2023

Study Completion Date

December 28, 2023

Conditions
Advanced Solid Tumor
Interventions
DRUG

IMGC936

Antibody Drug Conjugate

Trial Locations (13)

20089

IRCCS Humanitas, Rozzano

28040

START Madrid-FJD Hospital Universitario Fundacion Jimenez Diaz, Madrid

28050

START Madrid-HM CIOCC, Madrid

28223

Hospital Universitario Quirónsalud Madrid, Madrid

34232

Florida Cancer Specialists, Sarasota

41124

Policlinico di Modena, Modena

53100

Azienda Ospedaliera Universitaria Senese, Siena

63110

Washington University, St Louis

73104

Stephenson Cancer Center, Oklahoma City

77030

MD Anderson Cancer Center, Houston

80218

Sarah Cannon Research Institute, Denver

92037

UCSD, La Jolla

02215

Dana-Farber Cancer Institute, Boston

Sponsors

Lead Sponsor

ImmunoGen, Inc.

Collaborators (1)

MacroGenics
All Listed Sponsors
collaborator

MacroGenics

INDUSTRY

lead

ImmunoGen, Inc.

INDUSTRY

NCT04622774 - First-in-Human Study of IMGC936 in Participants With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter